A Prospective, Observational Study to Assess the Real-World Usage and Outcomes of HyQvia in Patients With Multiple Myeloma (MM) Diagnosed With Secondary Immunodeficiency (SID)
In this study, multiple myeloma participants with secondary immunodeficiency (SID) will be treated with HyQvia according to their clinic's standard practice. The study's main aim is to look into infusion parameters of HyQvia administration.
⁃ Participants who meet all of the following criteria assessed at the time of enrollment are eligible for this study:
• Ability and willingness to provide informed consent. For adult participants unable to provide informed consent, informed consent provided by the legally authorized representative (LAR).
• Has a diagnosis of MM requiring systemic anti-myeloma therapy as per International Myeloma Working Group (IMWG) criteria.
• Initiated HyQvia treatment as part of routine clinical care no more than 30 days before study enrollment or received no more than 2 doses of HyQvia treatment, whichever occurs first. Participants are also eligible if they newly start HyQvia within 30 days after the enrollment visit.
• Note: Participants who do not start HyQvia treatment within 30 days of enrollment will be considered as screen failures (and replaced).
• Age \>=18 years old at the time of MM diagnosis.
• Available medical history records starting from the diagnosis of MM requiring systemic anti-myeloma therapy as IMWG criteria.
• Life expectancy \>6 months at the time of enrollment, per physician assessment.
• Eastern Cooperative Oncology Group (ECOG) performance status score of \<=2.
• Participants/LAR willing and able to comply with the requirements of the protocol.